Almac Group has unveiled plans for a £375,000 (~$500mn) investment in additional NMR instrumentation at its global headquarters in Craigavon, UK.

As part of Almac Sciences’ state-of-the-art cGMP facility, enhanced NMR services will be offered to help deliver comprehensive solutions supporting drug substance (API) and drug product development programs from early phase to commercialization. These services include advanced characterization and purity assessment abilities in line with regulatory requirements. This investment boosts the existing Almac NMR testing service already available to clients.

The new 500MHz NMR instrument setup at Almac incorporates Bruker’s cutting-edge Avance Neo platform, in addition to a Prodigy Cryoprobe all within a temperature controlled environment. This provides greater flexibility, higher sensitivity and resolution. The capability to analyze nuclei from 15N to 31P, in addition to a wide range of 2D and quantitative NMR experiments, now allows Almac to increase its NMR service offering.

Almac’s dedicated NMR team has worked with many pharmaceutical companies providing novel solutions to their scientific problems, and now, with analysis running up to ten times faster, the increased through-put and capacity will increase efficiency and turnaround times. In addition, the latest software includes additional processing capabilities and provides superior data integrity controls which will ensure increasing regulatory compliance needs are met.